Health Care [ 9/12 ] | Biotechnology [ 61/74 ]
NASDAQ | Common Stock
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases.
The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015.
Altimmune, Inc. was founded in 1997 and is headquartered in Gaithersburg, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 25, 25 | -0.33 Increased by 0.00% | -0.34 Increased by +1.52% |
| Nov 5, 24 | -0.32 Increased by +17.59% | -0.35 Increased by +8.17% |
| Aug 8, 24 | -0.35 Decreased by -9.37% | -0.34 Decreased by -2.94% |
| May 14, 24 | -0.34 Increased by +15.00% | -0.37 Increased by +8.11% |
| Mar 27, 24 | -0.33 Increased by +23.26% | -0.43 Increased by +23.26% |
| Nov 7, 23 | -0.39 Increased by +18.75% | -0.42 Increased by +7.14% |
| Aug 10, 23 | -0.32 Increased by +23.81% | -0.46 Increased by +30.43% |
| May 11, 23 | -0.40 Increased by +9.09% | -0.48 Increased by +16.67% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 5.00 K Decreased by -86.49% | -23.18 M Increased by +26.74% | Decreased by -463.60 K% Decreased by -442.12% |
| Sep 30, 24 | 5.00 K Decreased by -98.62% | -22.84 M Decreased by -10.52% | Decreased by -456.90 K% Decreased by -7.90 K% |
| Jun 30, 24 | 5.00 K Decreased by -16.67% | -24.64 M Decreased by -53.42% | Decreased by -492.80 K% Decreased by -84.10% |
| Mar 31, 24 | 5.00 K Decreased by -76.19% | -24.39 M Decreased by -32.64% | Decreased by -487.88 K% Decreased by -457.09% |
| Dec 31, 23 | 37.00 K Increased by +133.64% | -31.64 M Decreased by -56.44% | Decreased by -85.52 K% Decreased by -565.08% |
| Sep 30, 23 | 362.00 K Increased by +18.00 K% | -20.67 M Increased by +12.10% | Decreased by -5.71 K% Increased by +99.51% |
| Jun 30, 23 | 6.00 K Decreased by -25.00% | -16.06 M Increased by +20.12% | Decreased by -267.68 K% Decreased by -6.50% |
| Mar 31, 23 | 21.00 K Decreased by -34.38% | -18.39 M Increased by +5.01% | Decreased by -87.58 K% Decreased by -44.75% |